SCHEMBL2366262

SCHEMBL2366262

Cc1cc(N2CCOC2=O)ncc1C(=O)N1CCN(c2ncc(Br)cc2C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.38
LMNA P02545 3/20 0.38
THRB P10828 2/20 0.38
KDM4E B2RXH2 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 3/20 0.36
GBA1 P04062 1/20 0.36
ALDH1A1 P00352 5/20 0.35
AKR1C3 P42330 1/20 0.35
KMT2A Q03164 3/20 0.35
EGLN1 Q9GZT9 1/20 0.35
HSD17B10 Q99714 2/20 0.35
RCE1 Q9Y256 1/20 0.35
MEN1 O00255 2/20 0.34
HPGD P15428 2/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12240532 0.90 LMNA (0.42) TP53LMNATHRBKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL2381522 0.89 LMNA (0.41) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL12240552 0.87 TP53 (0.37) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL12240551 0.86 LMNA (0.37) TP53LMNATHRBKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL2378161 0.86 TP53 (0.37) TP53LMNATHRBKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL2381826 0.85 LMNA (0.36) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL2366076 0.82 KDM4E (0.37) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL2366081 0.82 KDM4E (0.37) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL2366875 0.81 LMNA (0.36) TP53LMNATHRBKDM4ESMN1; SMN2
SCHEMBL12240550 0.80 LMNA (0.52) TP53LMNATHRBKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 TP53 1433/4885LMNA 3668/4885THRB 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.